ArticleBritish journal of cancer2026
Urinary proteome and metabolome uncover tumor microenvironment and cellular metabolism changes of renal clear cell carcinoma.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundClear cell renal carcinoma (ccRCC) is the most frequent form of kidney tumors with high recurrence and progression rates. Early diagnosis of ccRCC could significantly improve survival rate. Liquid biopsies could capture molecular information which would not only shed more light on the signatures of the onset of ccRCC, but also discover potential biomarker for early diagnosis.
methodWe applied LC-MS to profile the urine proteome and metabolome of 314 ccRCC, 341 healthy control and 49 kidney benign disease enrolled from three cohorts. Further cell origin annotation and protein-protein correlation analysis were performed to explain the possible TME mechanistic.
resultsWe revealed significant changes of extracellular matrix (ECM) organization, complement and coagulation cascades, amino acid metabolism and fatty acid metabolism in ccRCC. Cell origin annotation of cancer proteins revealed the potential role of myofibroblast cell during ECM organization. Finally, we discovered six potential urinary biomarkers, FGB,CILP, ITIH1, GUCA2B, anserine, oxindole and established models for ccRCC diagnosis with the AUC value of 0.84, 0.80 and 0.86 for protein model, metabolites model and multi-omics model in an external cohort. The protein model also showed discriminatory ability for ccRCC and benign with the AUC value of 0.75.
conclusionPresent study provided urinary molecular changes, which could reflect TME disorder and cellular metabolism reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.